BioSpace News Archive

Business

Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer

Flare Therapeutics Inc. today announced the appointment of Douglas Manion, M.D., FRCP (C), as Chief Executive Officer, effective immediately.

April 23, 2024
·
3 min read
Business

Tentarix Biotherapeutics Announces the Appointment of Andrew D. Kidd, MD, CFA, as CEO

Tentarix Biotherapeutics today announced the appointment of Andrew Kidd, MD, as chief executive officer.

April 23, 2024
·
1 min read
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment

Silo Pharma, Inc. today announced positive data in the final validation report from the recent pharmacokinetic (PK) study of SPC-15, an intranasal prophylactic treatment for anxiety and post-traumatic stress disorder (PTSD).

April 23, 2024
·
4 min read
Business

ICU Medical Announces Time of First Quarter 2024 Earnings Conference Call

ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its first quarter 2024 earnings release and conference call.

April 23, 2024
·
1 min read
Genetown

Wave Life Sciences Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and RNA Editing

Wave Life Sciences Ltd. provided an update on its best-in-class small interfering RNA and RNA editing platform capabilities.

April 23, 2024
·
6 min read
Business

Halozyme to Report First Quarter 2024 Financial and Operating Results

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme”) today announced it will release its first quarter 2024 financial and operating results on Tuesday, May 7, 2024, following the close of trading.

April 23, 2024
·
2 min read
Lone Star Bio

Hera Biotech Announces Positive Interim Results From Endometriosis Diagnostic Study

Hera Biotech is pleased to report the interim results for its proof-of-concept multi-center clinical trial of the MetriDx™ endometriosis diagnostic test.

April 23, 2024
·
4 min read
Drug Development

Alto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for Schizophrenia

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced positive results from its healthy volunteer Phase 1 study of ALTO-101, a novel PDE4 inhibitor in development for cognitive impairment associated with schizophrenia (CIAS).

April 23, 2024
·
7 min read
Drug Development

Response Pharmaceuticals’ Drug Candidate for the Treatment of Antipsychotic-Induced Weight Gain (AIWG) Achieves Primary Endpoint in Phase 1b Clinical Trial

Response Pharmaceuticals, Inc today announced positive topline results from its Phase 1b clinical trial evaluating the safety and efficacy of RDX-002.

April 23, 2024
·
6 min read
BioMidwest

MAIA Biotechnology Announces $1.00 Million Private Placement

MAIA Biotechnology, Inc. announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 494,096 shares of common stock at a purchase price of $2.034 per share, in a private placement to accredited investors and certain Company directors.

April 23, 2024
·
5 min read